BCL2L11 (Bcl-2-like protein 11) variants and mutations
BCL2L11 (also known as Bcl-2-like protein 11) is a human protein-coding gene encoding a bcl-2-like protein 11 protein. Its BIM isoforms act as potent initiators of intrinsic apoptosis by neutralizing anti-apoptotic BCL-2-family proteins and activating BAX or BAK. Reduced BIM activity can promote treatment resistance, particularly in cancers dependent on survival signaling. This analysis covers 617 BCL2L11 variants and mutations. Of these, 80% have computational variant effect predictions. Disease context includes cancer, neurodegenerative disease, and prostate carcinoma. Example BCL2L11 variants include A2G, A2T, and A2S.
Variant analysis overview
- Gene: BCL2L11
- Protein: Bcl-2-like protein 11
- UniProt accession: O43521
- Organism: Homo sapiens
- Variants analyzed: 617
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 392 unspecified-consequence records; 115 missense variants; 79 synonymous variants; 10 stop-gained variants; 4 in-frame deletions; 10 frameshift variants; 2 splice-region variants; 1 stop lost; 4 substitution
- Prediction scores: 491 variants have prediction scores (80% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: cancer, neurodegenerative disease, prostate carcinoma, asthma, type 2 diabetes mellitus, diabetes mellitus, B-cell chronic lymphocytic leukemia, breast cancer, Umbilical hernia, lymphoid leukemia, Abnormality of the skeletal system, rheumatoid arthritis.
Protein structure and variant hotspots
- Protein features: 4 post-translational modification sites.
- PTM context: 9 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable BCL2L11 variants
Examples include A2G, A2T, A2S, A2E, A2V, K3E, K3N, K3R. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2G (p.Ala2Gly), ExAC rs756367205, gnomAD rs756367205, REVEL 0.24, MetaLR 0.26
- A2T (p.Ala2Thr), NCI-TCGA Cosmic COSV5803, cosmic curated COSV58031, REVEL 0.30, MetaLR 0.26, Variant assessed as somatic; moderate impact.
- A2S (p.Ala2Ser), gnomAD 2-111123749-G-T, REVEL 0.27, MetaLR 0.26
- A2E (p.Ala2Glu), gnomAD 2-111123750-C-A, REVEL 0.35, MetaLR 0.26
- A2V (p.Ala2Val), gnomAD 2-111123750-C-T, REVEL 0.49, MetaLR 0.26
- K3E (p.Lys3Glu), gnomAD rs2071805543, REVEL 0.65, MetaLR 0.25
- K3N (p.Lys3Asn), ExAC rs777927181, TOPMed rs777927181, gnomAD rs777927181
- K3R (p.Lys3Arg), TOPMed rs2071806023, REVEL 0.23, MetaLR 0.25
- K3K (p.Lys3Lys), rs777927181, gnomAD 2-111123754-G-A, CADD 12.70
- Q4L (p.Gln4Leu), TOPMed rs1215949589, MetaLR 0.24, MetaSVM -0.58
- Q4* (p.Gln4Ter), gnomAD 2-111123755-C-T, CADD 37.00
- Q4Q (p.Gln4Gln), rs1028206513, gnomAD 2-111123757-A-G, CADD 12.20
- P5A (p.Pro5Ala), TOPMed rs1250218441, gnomAD rs1250218441, REVEL 0.53, MetaLR 0.26
- P5H (p.Pro5His), ExAC rs749642894, TOPMed rs749642894, gnomAD rs749642894, REVEL 0.45, MetaLR 0.26
- P5L (p.Pro5Leu), rs749642894, ExAC rs749642894, TOPMed rs749642894, gnomAD rs749642894, REVEL 0.37, MetaLR 0.26, Variant assessed as somatic; moderate impact.
- P5S (p.Pro5Ser), rs1250218441, NCI-TCGA Cosmic COSV1004, cosmic curated COSV10042, TOPMed rs1250218441, REVEL 0.52, MetaLR 0.26, Variant assessed as somatic; moderate impact.
- P5T (p.Pro5Thr), gnomAD 2-111123758-C-A, REVEL 0.41, MetaLR 0.26
- P5P (p.Pro5Pro), rs774796514, gnomAD 2-111123760-T-A, CADD 14.20
- S6Y (p.Ser6Tyr), TOPMed rs1219836031, gnomAD rs1219836031, REVEL 0.33, MetaLR 0.26
- S6A (p.Ser6Ala), gnomAD 2-111123761-T-G, REVEL 0.48, MetaLR 0.24
- S6C (p.Ser6Cys), gnomAD 2-111123762-C-G, REVEL 0.32, MetaLR 0.26
- S6S (p.Ser6Ser), rs1041637510, gnomAD 2-111123763-T-C, CADD 5.22
- D7Y (p.Asp7Tyr), gnomAD 2-111123764-G-T, REVEL 0.33, MetaLR 0.26
- D7G (p.Asp7Gly), gnomAD 2-111123765-A-G, REVEL 0.28, MetaLR 0.18
- V8E (p.Val8Glu), gnomAD 2-111123768-T-A, REVEL 0.33, MetaLR 0.15
- V8V (p.Val8Val), gnomAD 2-111123769-A-G, CADD 13.40
- S9R (p.Ser9Arg), gnomAD 2-111123770-A-C, REVEL 0.18, MetaLR 0.13
- S9I (p.Ser9Ile), gnomAD 2-111123771-G-T, REVEL 0.13, MetaLR 0.10
- S10Y (p.Ser10Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- E11A (p.Glu11Ala), Ensembl rs2071810360
- E11Q (p.Glu11Gln), ExAC rs746394040
- E11* (p.Glu11Ter), gnomAD 2-111123776-G-T, CADD 39.00
- E11G (p.Glu11Gly), gnomAD 2-111123777-A-G, REVEL 0.29, MetaLR 0.24
- E11D (p.Glu11Asp), gnomAD 2-111123778-G-T, REVEL 0.20, MetaLR 0.10
- C12Y (p.Cys12Tyr), TOPMed rs900900854
- C12F (p.Cys12Phe), gnomAD 2-111123780-G-T, REVEL 0.70, MetaLR 0.26
- D13E (p.Asp13Glu), 1000Genomes rs112446582, ESP rs112446582, ExAC rs112446582, TOPMed rs112446582, REVEL 0.07, MetaLR 0.15, Benign
- D13Y (p.Asp13Tyr), gnomAD 2-111123782-G-T, REVEL 0.28, MetaLR 0.19
- D13G (p.Asp13Gly), gnomAD 2-111123783-A-G, REVEL 0.23, MetaLR 0.24
- D13D (p.Asp13Asp), rs112446582, gnomAD 2-111123784-C-T, CADD 11.60
- R14G (p.Arg14Gly), rs1041372390, ClinGen CA54112328, ClinVar RCV004185318, TOPMed rs1041372390, REVEL 0.22, MetaLR 0.17, Uncertain significance, not specified
- R14* (p.Arg14Ter), gnomAD 2-111123785-C-T, CADD 35.00
- R14R (p.Arg14Arg), gnomAD 2-111123785-C-A, CADD 9.29
- R14Q (p.Arg14Gln), gnomAD 2-111123786-G-A, REVEL 0.16, MetaLR 0.20
- R14P (p.Arg14Pro), gnomAD 2-111123786-G-C, REVEL 0.22, MetaLR 0.24
- R14L (p.Arg14Leu), gnomAD 2-111123786-G-T, REVEL 0.26, MetaLR 0.24
- E15G (p.Glu15Gly), Ensembl rs2071813812, MetaLR 0.19, MetaSVM -0.73
- E15K (p.Glu15Lys), ExAC rs776207874, TOPMed rs776207874, gnomAD rs776207874, REVEL 0.27, MetaLR 0.26
- E15Q (p.Glu15Gln), ExAC rs776207874, TOPMed rs776207874, gnomAD rs776207874, REVEL 0.22, MetaLR 0.26
- G16S (p.Gly16Ser), Ensembl rs1014619723, REVEL 0.40, MetaLR 0.27
- G16G (p.Gly16Gly), gnomAD 2-111123793-T-C, CADD 10.90
- Q18Q (p.Gln18Gln), rs140468882, gnomAD 2-111123799-A-G, CADD 8.69
- L19M (p.Leu19Met), gnomAD 2-111123800-T-A, REVEL 0.24, MetaLR 0.19
- p.Leu19 Pro26delinsPhe, gnomAD 2-111123801-TGCAG, CADD 20.20
- L19L (p.Leu19Leu), rs904192007, gnomAD 2-111123802-G-A, CADD 10.90
- Q20H (p.Gln20His), gnomAD rs2071816472, REVEL 0.21, MetaLR 0.19
- Q20* (p.Gln20Ter), gnomAD 2-111123803-C-T, CADD 37.00
- Q20K (p.Gln20Lys), gnomAD 2-111123803-C-A, REVEL 0.11, MetaLR 0.22
- Q20E (p.Gln20Glu), gnomAD 2-111123803-C-G, REVEL 0.07, MetaLR 0.16
- Q20Q (p.Gln20Gln), gnomAD 2-111123805-G-A, CADD 8.65
- P21S (p.Pro21Ser), ExAC rs764939886, gnomAD rs764939886, REVEL 0.18, MetaLR 0.17
- P21T (p.Pro21Thr), gnomAD 2-111123806-C-A, REVEL 0.15, MetaLR 0.20
- P21A (p.Pro21Ala), gnomAD 2-111123806-C-G, REVEL 0.18, MetaLR 0.19
- P21L (p.Pro21Leu), gnomAD 2-111123807-C-T, REVEL 0.28, MetaLR 0.26
- A22E (p.Ala22Glu), gnomAD rs1429573443, REVEL 0.11, MetaLR 0.16
- A22V (p.Ala22Val), rs1429573443, cosmic curated COSV10880, gnomAD rs1429573443, REVEL 0.08, MetaLR 0.09, Variant assessed as somatic; moderate impact.
- A22T (p.Ala22Thr), gnomAD 2-111123809-G-A, REVEL 0.01, MetaLR 0.04
- A22S (p.Ala22Ser), gnomAD 2-111123809-G-T, REVEL 0.05, MetaLR 0.05
- A22A (p.Ala22Ala), rs773039812, gnomAD 2-111123811-G-T, CADD 2.59
- E23G (p.Glu23Gly), Ensembl rs1286273190, REVEL 0.15, MetaLR 0.13
- E23* (p.Glu23Ter), gnomAD 2-111123812-G-T, CADD 38.00
- R24M (p.Arg24Met), TOPMed rs2071819097
- R24G (p.Arg24Gly), gnomAD 2-111123815-A-G, REVEL 0.16, MetaLR 0.16
- R24R (p.Arg24Arg), gnomAD 2-111123817-G-A, CADD 11.80
- R24S (p.Arg24Ser), gnomAD 2-111123817-G-C, REVEL 0.21, MetaLR 0.17
- P25R (p.Pro25Arg), Ensembl rs1327265816, REVEL 0.21, MetaLR 0.20
- P25T (p.Pro25Thr), gnomAD 2-111123818-C-A, REVEL 0.35, MetaLR 0.26
- P25S (p.Pro25Ser), gnomAD 2-111123818-C-T, REVEL 0.24, MetaLR 0.26
- P26A (p.Pro26Ala), ExAC rs762820125, TOPMed rs762820125, gnomAD rs762820125, REVEL 0.05, MetaLR 0.05
- P26H (p.Pro26His), TOPMed rs375839187, gnomAD rs375839187, REVEL 0.08, MetaLR 0.09
- P26L (p.Pro26Leu), rs375839187, NCI-TCGA Cosmic COSV1004, cosmic curated COSV10042, TOPMed rs375839187, REVEL 0.08, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- P26S (p.Pro26Ser), rs762820125, NCI-TCGA Cosmic COSV1004, cosmic curated COSV10042, ExAC rs762820125, REVEL 0.05, MetaLR 0.06, Variant assessed as somatic; moderate impact.
- P26T (p.Pro26Thr), ExAC rs762820125, TOPMed rs762820125, gnomAD rs762820125, REVEL 0.04, MetaLR 0.06
- P26P (p.Pro26Pro), rs1421729917, gnomAD 2-111123823-C-G, CADD 10.50
- Q27P (p.Gln27Pro), TOPMed rs1303900837, gnomAD rs1303900837, REVEL 0.17, MetaLR 0.19
- Q27S (p.Gln27Ser), gnomAD 2-111123820-TC-T, CADD 23.90
- Q27K (p.Gln27Lys), gnomAD 2-111123824-C-A, REVEL 0.15, MetaLR 0.24
- Q27R (p.Gln27Arg), gnomAD 2-111123825-A-G, REVEL 0.20, MetaLR 0.16
- Q27H (p.Gln27His), gnomAD 2-111123826-G-C, REVEL 0.21, MetaLR 0.15
- L28F (p.Leu28Phe), ExAC rs766299103, TOPMed rs766299103, gnomAD rs766299103, REVEL 0.27, MetaLR 0.26
- L28P (p.Leu28Pro), gnomAD rs1403383759, REVEL 0.43, MetaLR 0.24
- L28V (p.Leu28Val), ExAC rs766299103, TOPMed rs766299103, gnomAD rs766299103, REVEL 0.16, MetaLR 0.26, Uncertain significance, not specified
- L28L (p.Leu28Leu), rs754945502, gnomAD 2-111123829-C-T, CADD 12.20
- R29G (p.Arg29Gly), rs2468256670, ClinGen CA348351551, ClinVar RCV004104411, REVEL 0.32, MetaLR 0.18, Uncertain significance, not specified
- R29* (p.Arg29Ter), gnomAD 2-111123830-A-T, CADD 36.00
- R29I (p.Arg29Ile), gnomAD 2-111123831-G-T, REVEL 0.58, MetaLR 0.26
- R29R (p.Arg29Arg), rs2071825328, gnomAD 2-111123832-A-G, CADD 12.60
- R29S (p.Arg29Ser), gnomAD 2-111123832-A-C, REVEL 0.30, MetaLR 0.15
- P30H (p.Pro30His), TOPMed rs1363842751, gnomAD rs1363842751, REVEL 0.19, MetaLR 0.15
- P30L (p.Pro30Leu), TOPMed rs1363842751, gnomAD rs1363842751, REVEL 0.15, MetaLR 0.11
- P30S (p.Pro30Ser), TOPMed rs1195836135, gnomAD rs1195836135, REVEL 0.10, MetaLR 0.06
- P30T (p.Pro30Thr), gnomAD 2-111123833-C-A, REVEL 0.13, MetaLR 0.06
- P30P (p.Pro30Pro), rs1252809755, gnomAD 2-111123835-T-C, CADD 12.50
- G31E (p.Gly31Glu), NCI-TCGA Cosmic COSV1004, cosmic curated COSV10042, Variant assessed as somatic; moderate impact.
- G31R (p.Gly31Arg), NCI-TCGA Cosmic COSV1004, cosmic curated COSV10042, REVEL 0.49, MetaLR 0.26, Variant assessed as somatic; moderate impact.
- G31W (p.Gly31Trp), gnomAD 2-111123832-A-AC, CADD 25.00
- G31G (p.Gly31Gly), gnomAD 2-111123838-G-C, CADD 13.00
- A32T (p.Ala32Thr), cosmic curated COSV58032, ExAC rs200974474, TOPMed rs200974474, gnomAD rs200974474, REVEL 0.42, MetaLR 0.27, Uncertain significance, not specified
- A32V (p.Ala32Val), gnomAD rs1340037091, REVEL 0.51, MetaLR 0.26
- A32P (p.Ala32Pro), gnomAD 2-111123835-TG-T, CADD 28.50
- A32D (p.Ala32Asp), gnomAD 2-111123840-C-A, REVEL 0.41, MetaLR 0.27
- P33L (p.Pro33Leu), ESP rs370683853, ExAC rs370683853, TOPMed rs370683853, gnomAD rs370683853, REVEL 0.35, MetaLR 0.26
- P33R (p.Pro33Arg), ESP rs370683853, ExAC rs370683853, TOPMed rs370683853, gnomAD rs370683853, REVEL 0.28, MetaLR 0.27
- P33P (p.Pro33Pro), gnomAD 2-111123844-T-A, CADD 9.07
- T34A (p.Thr34Ala), ESP rs151214891, TOPMed rs151214891, gnomAD rs151214891, REVEL 0.06, MetaLR 0.19
- T34P (p.Thr34Pro), ESP rs151214891, TOPMed rs151214891, gnomAD rs151214891, REVEL 0.22, MetaLR 0.19
- T34S (p.Thr34Ser), gnomAD 2-111123845-A-T, REVEL 0.06, MetaLR 0.16
- T34N (p.Thr34Asn), gnomAD 2-111123846-C-A, REVEL 0.04, MetaLR 0.19
- T34I (p.Thr34Ile), gnomAD 2-111123846-C-T, REVEL 0.05, MetaLR 0.19
- T34T (p.Thr34Thr), gnomAD 2-111123847-C-A, CADD 12.80
- S35C (p.Ser35Cys), gnomAD rs979302636, REVEL 0.27, MetaLR 0.25
- S35P (p.Ser35Pro), rs2468257545, ClinGen CA348351586, ClinVar RCV004426287, Uncertain significance, not specified
- S35Y (p.Ser35Tyr), gnomAD rs979302636
- S35A (p.Ser35Ala), gnomAD 2-111123848-T-G, REVEL 0.25, MetaLR 0.18
- S35F (p.Ser35Phe), gnomAD 2-111123849-C-T, REVEL 0.31, MetaLR 0.26
- S35S (p.Ser35Ser), gnomAD 2-111123850-C-T, CADD 11.20
- L36V (p.Leu36Val), ExAC rs749538495, TOPMed rs749538495, gnomAD rs749538495, REVEL 0.06, MetaLR 0.06
- L36L (p.Leu36Leu), rs749538495, gnomAD 2-111123851-C-T, CADD 11.70
- Q37* (p.Gln37Ter), TOPMed rs1305141595, gnomAD rs1305141595, CADD 36.00
- Q37R (p.Gln37Arg), Ensembl rs762177415, REVEL 0.06, MetaLR 0.02
- Q37Q (p.Gln37Gln), gnomAD 2-111123856-G-A, CADD 7.65
- T38A (p.Thr38Ala), Ensembl rs1559009310, REVEL 0.12, MetaLR 0.05
- T38R (p.Thr38Arg), ExAC rs770466826, TOPMed rs770466826, gnomAD rs770466826, REVEL 0.07, MetaLR 0.07
- T38I (p.Thr38Ile), gnomAD 2-111123858-C-T, REVEL 0.09, MetaLR 0.06
- T38T (p.Thr38Thr), rs2071834607, gnomAD 2-111123859-A-G, CADD 12.40
- E39K (p.Glu39Lys), TOPMed rs1369969496, gnomAD rs1369969496, REVEL 0.10, MetaLR 0.05
- E39V (p.Glu39Val), TOPMed rs2071835476
- E39D (p.Glu39Asp), gnomAD 2-111123852-T-TAC, CADD 26.00
- E39A (p.Glu39Ala), gnomAD 2-111123858-CAG-C, CADD 29.50
- E39E (p.Glu39Glu), rs746318678, gnomAD 2-111123862-G-A, CADD 9.76
- P40L (p.Pro40Leu), Ensembl rs2071836166, REVEL 0.06, MetaLR 0.05
- P40Q (p.Pro40Gln), gnomAD 2-111123864-C-A, REVEL 0.03, MetaLR 0.05
- P40P (p.Pro40Pro), gnomAD 2-111123865-A-G, CADD 8.65
- Q41E (p.Gln41Glu), gnomAD 2-111123866-C-G, REVEL 0.07, MetaLR 0.12
- Q41Q (p.Gln41Gln), gnomAD 2-111123868-A-G, CADD 15.50
- G42C (p.Gly42Cys), gnomAD rs1447050253, REVEL 0.24, MetaLR 0.19
- N43D (p.Asn43Asp), rs776156195, ClinGen CA1829289, ClinVar RCV004178078, ExAC rs776156195, REVEL 0.11, CADD 25.40, Uncertain significance, not specified
- N43S (p.Asn43Ser), ExAC rs775928756, gnomAD rs775928756, REVEL 0.12, CADD 24.30
- N43Y (p.Asn43Tyr), ExAC rs776156195, TOPMed rs776156195, gnomAD rs776156195, REVEL 0.21, CADD 32.00, Uncertain significance
- P44L (p.Pro44Leu), gnomAD rs988452389, REVEL 0.04, CADD 15.10
- P44S (p.Pro44Ser), gnomAD 2-111123875-C-T, REVEL 0.04, CADD 22.90
- P44R (p.Pro44Arg), gnomAD 2-111123876-C-G, REVEL 0.04, CADD 19.30
- E45K (p.Glu45Lys), Ensembl rs2071838875
- E45E (p.Glu45Glu), rs1161599296, gnomAD 2-111123880-A-G, CADD 11.50
- G46D (p.Gly46Asp), gnomAD 2-111123882-G-A, REVEL 0.36, CADD 23.40
- N47I (p.Asn47Ile), 1000Genomes rs199602272, ESP rs199602272, ExAC rs199602272, TOPMed rs199602272, REVEL 0.08, CADD 9.61, Uncertain significance
- N47S (p.Asn47Ser), rs199602272, ClinGen CA1829291, cosmic curated COSV58027, ClinVar RCV004237665, REVEL 0.25, CADD 1.63, Uncertain significance, not specified
- H48Q (p.His48Gln), TOPMed rs1444228486, gnomAD rs1444228486, REVEL 0.05, CADD 5.72
- p.His48 Pro60del, gnomAD 2-111123885-ATCAC, CADD 19.70
- H48H (p.His48His), gnomAD 2-111123889-C-T, CADD 3.05
- G49* (p.Gly49Ter), NCI-TCGA Cosmic COSV5802, NCI-TCGA Cosmic COSV5803, Variant assessed as somatic; high impact.
- G49E (p.Gly49Glu), cosmic curated COSV58029, ExAC rs769237808, gnomAD rs769237808, REVEL 0.14, CADD 14.80
- G49R (p.Gly49Arg), rs1431222585, NCI-TCGA Cosmic COSV5802, NCI-TCGA Cosmic COSV5803, cosmic curated COSV58032, REVEL 0.10, CADD 22.30, Variant assessed as somatic; moderate impact.
- G50D (p.Gly50Asp), 1000Genomes rs2150141204, REVEL 0.18, CADD 12.80
- G50R (p.Gly50Arg), rs772949984, ClinGen CA1829293, cosmic curated COSV10735, ClinVar RCV004205487, REVEL 0.12, CADD 19.80, Uncertain significance, not specified
- G50S (p.Gly50Ser), ExAC rs772949984, gnomAD rs772949984, REVEL 0.11, CADD 15.80, Uncertain significance
- G50V (p.Gly50Val), gnomAD 2-111123894-G-T, REVEL 0.14, CADD 13.40
- G50G (p.Gly50Gly), gnomAD 2-111123895-T-C, CADD 7.60
- E51D (p.Glu51Asp), ExAC rs766209148, TOPMed rs766209148, gnomAD rs766209148, REVEL 0.04, CADD 18.50
- E51K (p.Glu51Lys), NCI-TCGA Cosmic COSV5802, cosmic curated COSV58027, REVEL 0.05, CADD 23.50, Variant assessed as somatic; moderate impact.
- E51E (p.Glu51Glu), rs766209148, gnomAD 2-111123898-A-G, CADD 13.00
- p.Glu76 Asp77del, gnomAD 2-111128636-TAGAG, CADD 1.42
- E51Q (p.Glu51Gln), gnomAD 2-111128638-G-C, CADD 0.10, SIFT 0.73
- E51* (p.Glu51Ter), gnomAD 2-111128638-G-T, CADD 0.10
- E51G (p.Glu51Gly), gnomAD 2-111128639-A-G, CADD 0.79, SIFT 0.13
- E51V (p.Glu51Val), gnomAD 2-111128639-A-T, CADD 0.64, SIFT 0.10
- E51A (p.Glu51Ala), rs866869532, []
- G52E (p.Gly52Glu), ExAC rs759304312, TOPMed rs759304312, gnomAD rs759304312, REVEL 0.25, CADD 26.00
- G52R (p.Gly52Arg), ExAC rs774299408, TOPMed rs774299408, gnomAD rs774299408, REVEL 0.22, CADD 26.20
- G52G (p.Gly52Gly), gnomAD 2-111123901-G-A, CADD 10.70
Public BCL2L11 analysis runs
- BCL2L11 analysis run — BCL2L11 (617 variants) — completed 2026-08-20